Pluristem Therapeutics Inc (PSTI)

[Auto1]

"We have the capacity to make 150,000 doses of commercial grade PLX cells at this time..."

FDApproved
Saturday, 05/06/17 08:05:08 PM
Re: None
0
Post # of 18685


Scaling-Up PLX-Cell Production Will Not Be An Issue For Pluristem


Excerpt From An Interview With Yaky Yanay Last November 29th

"Commercial manufacturing is a critical bottleneck in the space. Many people are now focused on this challenge, because if new technology is needed to produce commercial quantities of cells, one runs the risk of changing the cell characteristics by growing them with different technology. In contrast with others in our space, we have our own FDA and EU-approved manufacturing facility through commercialization meaning if and when our products reach approval, we are already cleared to use our own manufacturing facilities to commercialize them. We have the capacity to make 150,000 doses of commercial grade PLX cells at this time, and to increase capacity we need only scale out with additional bioreactors. We do not need to modify the patented production technology. We can make 20,000 doses from a single placenta, and this efficiency is because of our patented manufacturing technology and our placental cell source."

https://marketexclusive.com/exclusive-interview-pluristem-therapeutics-inc-nasdaqpsti-president-yaky-yanay/41188/


FDApproved
Saturday, 05/06/17 08:05:08 PM
Re: None
0
Post # of 18685


Scaling-Up PLX-Cell Production Will Not Be An Issue For Pluristem


Excerpt From An Interview With Yaky Yanay Last November 29th

"Commercial manufacturing is a critical bottleneck in the space. Many people are now focused on this challenge, because if new technology is needed to produce commercial quantities of cells, one runs the risk of changing the cell characteristics by growing them with different technology. In contrast with others in our space, we have our own FDA and EU-approved manufacturing facility through commercialization meaning if and when our products reach approval, we are already cleared to use our own manufacturing facilities to commercialize them. We have the capacity to make 150,000 doses of commercial grade PLX cells at this time, and to increase capacity we need only scale out with additional bioreactors. We do not need to modify the patented production technology. We can make 20,000 doses from a single placenta, and this efficiency is because of our patented manufacturing technology and our placental cell source."

https://marketexclusive.com/exclusive-interview-pluristem-therapeutics-inc-nasdaqpsti-president-yaky-yanay/41188/


FDApproved
Saturday, 05/06/17 08:05:08 PM
Re: None
0
Post # of 18685


Scaling-Up PLX-Cell Production Will Not Be An Issue For Pluristem


Excerpt From An Interview With Yaky Yanay Last November 29th

"Commercial manufacturing is a critical bottleneck in the space. Many people are now focused on this challenge, because if new technology is needed to produce commercial quantities of cells, one runs the risk of changing the cell characteristics by growing them with different technology. In contrast with others in our space, we have our own FDA and EU-approved manufacturing facility through commercialization meaning if and when our products reach approval, we are already cleared to use our own manufacturing facilities to commercialize them. We have the capacity to make 150,000 doses of commercial grade PLX cells at this time, and to increase capacity we need only scale out with additional bioreactors. We do not need to modify the patented production technology. We can make 20,000 doses from a single placenta, and this efficiency is because of our patented manufacturing technology and our placental cell source."

https://marketexclusive.com/exclusive-interview-pluristem-therapeutics-inc-nasdaqpsti-president-yaky-yanay/41188/